- In November 2024, Quanta Dialysis Technologies has received FDA 510(k) clearance for its Quanta Dialysis System for use in home settings, making it the only company to offer a high dialysate flow (500 mL/min) system across the entire care continuum for ESRD patients. This approval strengthens Quanta’s position in the home dialysis market, enhancing its competitiveness and expanding its customer base
- In October 2024, Nephro Care India Limited (NCIL) is working with the National Institute of Technology, Silchar, to develop a prototype of a remotely monitored, AI-enabled Smart Haemodialysis Machine. This collaboration will enhance the company’s ability to offer innovative, advanced dialysis solutions, improving patient care and expanding its market presence
- In September 2024, Fresenius Medical Care (FME) has reached a milestone of over 14,000 U.S. patients using its NxStage systems for Home Hemodialysis (HHD) therapy, offered through Fresenius Kidney Care clinics and other providers. The company also launched the NxStage VersiHD with GuideMe Software, which enhances treatment simplicity, learning ease, and user experience. This will help the company strengthen its leadership in home dialysis solutions and drive further growth in the market
- In August 2024, Baxter International Inc. has entered into an agreement with Carlyle to sell its Kidney Care segment, which will be renamed Vantive, for USD 3.8 billion. This transaction will enable Baxter to streamline its focus on core businesses while providing Carlyle with an opportunity to enhance and expand Vantive’s presence in the kidney care market
